Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

[A qualitative study on the procurement and management of non-national immunization program vaccines at county level in three provinces and one municipality of China].

Created on 16 Nov 2026

Authors

J Y Sai, Y Yu, H F Sun, G J Luan, C B Li, H Zhang, W Y Zhang, A Q Xu, W Z Yu

Published in

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]. Volume 60. Issue 11. Pages 1789-1794. Nov 06, 2026.

Abstract

Objective: To conduct a qualitative investigation into the procurement and management of non-National Immunization Program (non-NIP) vaccines at the county level in Shandong Province, Anhui Province, Gansu Province, and Shanghai City (three provinces and one municipality in China). Methods: In November 2024, semi-structured interviews were conducted with 65 leaders and key personnel from health administration and CDC departments across 30 counties in three provinces and one municipality. Topics included non-NIP vaccine procurement roles, selection processes, existing risks, and recommendations. Data were analyzed using NVivo Plus 11. Results: Interviews were conducted with 65 leaders from health administration and CDC departments. Results showed that 96.92% (63/65) of the interviewees mentioned the selection process of non-NIP vaccines. Among them, 36.51% (23/63) of participants reported that their respective counties had not conducted secondary selection for non-NIP vaccines due to provincial listing (10/23, 43.48%), lack of criteria (8/23, 34.78%), or insufficient capacity (8/23, 34.78%). Purposes for conducting secondary selection included streamlining categories (22/40, 55.00%), improving suitability (12/40, 30.00%), and anti-corruption (6/40, 15.00%). The potential risk issues faced in the procurement management of non-NIP vaccines were secondary selection (44/65, 67.69%), fund turnover difficulties (22/65, 33.85%), cold chain storage and transportation risks (18/65, 27.69%), vaccine pricing (14/65, 21.54%), and inadequate financial guarantees (10/65, 15.38%). Recommendations included strengthening scientific selection (29/65, 44.62%), comprehensive supervision (26/65, 40.00%), and financial support (20/65, 30.77%). Conclusion: Certain risks, such as secondary selection, fund management, cold chain management, and financial guarantees, exist in the procurement and management of non-NIP vaccines.

PMID:
43035296
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 2
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement